UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 254

Sortiert nach

Etravirine concentrations in CSF in HIV-infected patients

Journal of antimicrobial chemotherapy, 2012-06, Vol.67 (6), p.1446-1448

2012

Link zum Volltext

Verfügbarkeit prüfen

Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations

HIV medicine, 2021-08, Vol.22 (7), p.581-591

2021

Link zum Volltext

Verfügbarkeit prüfen

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study

Journal of neurovirology, 2018-02, Vol.24 (1), p.98-105

2018

Link zum Volltext

Verfügbarkeit prüfen

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study

Journal of antimicrobial chemotherapy, 2018-08, Vol.73 (8), p.2171-2176

2018

Link zum Volltext

Verfügbarkeit prüfen

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV‐1‐associated neurocognitive impairment during antiretroviral treatment switch

HIV medicine, 2015-07, Vol.16 (6), p.388-392

2015

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group

Journal of antimicrobial chemotherapy, 2014-05, Vol.69 (5), p.1390-1396

2014

Link zum Volltext

Verfügbarkeit prüfen

Elvitegravir concentrations in seminal plasma in HIV‐1‐infected men

HIV medicine, 2017-03, Vol.18 (3), p.225-230

2017

Link zum Volltext

Verfügbarkeit prüfen

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study

Journal of neurovirology, 2018-06, Vol.24 (3), p.388-389

2018

Link zum Volltext

Verfügbarkeit prüfen

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

HIV medicine, 2014-07, Vol.15 (6), p.330-338

2014

Link zum Volltext

Verfügbarkeit prüfen

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

Open forum infectious diseases, 2022-03, Vol.9 (3), p.ofab595-ofab595

2022

Link zum Volltext

Verfügbarkeit prüfen

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the ARTEN study)

HIV medicine, 2011-07, Vol.12 (6), p.374-382

2011

Link zum Volltext

Verfügbarkeit prüfen

Etravirine concentrations in seminal plasma in HIV-infected patients

Journal of antimicrobial chemotherapy, 2013-01, Vol.68 (1), p.184-187

2013

Link zum Volltext

Verfügbarkeit prüfen

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort

Clinical microbiology and infection, 2013-07, Vol.19 (7), p.646-653

2013

Link zum Volltext

Verfügbarkeit prüfen

New patterns of HIV-1 resistance during HAART

Clinical microbiology and infection, 2003-11, Vol.9 (11), p.1077-1084

2003

Link zum Volltext

Verfügbarkeit prüfen

Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients

Journal of antimicrobial chemotherapy, 2014-09, Vol.69 (9), p.2536-2540

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Prognosis of HIV-Infected Patients with Kaposi Sarcoma Treated with Pegylated Liposomal Doxorubicin

Clinical infectious diseases, 2008-08, Vol.47 (3), p.410-417

2008

Link zum Volltext

Verfügbarkeit prüfen

Trends in mortality and antibiotic resistance among HIV‐infected patients with invasive pneumococcal disease

HIV medicine, 2009-09, Vol.10 (8), p.488-495

2009

Link zum Volltext

Verfügbarkeit prüfen

Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144‐week final data from the STOPAR study

HIV medicine, 2012-09, Vol.13 (8), p.488-498

2012

Link zum Volltext

Verfügbarkeit prüfen

Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)

HIV medicine, 2011-08, Vol.12 (7), p.438-441

2011

Link zum Volltext

Verfügbarkeit prüfen

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study

Annals of internal medicine, 2020-10, Vol.173 (7), p.536

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease

European journal of clinical microbiology & infectious diseases, 2008-01, Vol.27 (1), p.65-73

2008

Link zum Volltext

Verfügbarkeit prüfen

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2222-2231

2014

Link zum Volltext

Verfügbarkeit prüfen

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

The Lancet infectious diseases, 2015-07, Vol.15 (7), p.785-792

2015

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 infected patients older than 50 years. PISCIS cohort study

The Journal of infection, 2008-07, Vol.57 (1), p.64-71

2008

Link zum Volltext

Verfügbarkeit prüfen

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

AIDS (London), 2012-11, Vol.26 (18), p.2315-2326

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 254

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(234)
Mit Volltextzugriff
(183)

Publikationsform

Artikel
(251)
Berichte
(3)

Sprache

Englisch
(215)
Spanisch
(40)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(190)
Life Sciences & Biomedicine
(162)
Science & Technology
(162)
Male
(146)
Adult
(145)
Infectious Diseases
(140)
Female
(130)
Hiv Infections - Drug Therapy
(100)
Middle Aged
(100)
Human Immunodeficiency Virus
(91)
Aids/hiv
(81)
Biological And Medical Sciences
(81)
Medical Sciences
(80)
Hiv
(79)
Immunology
(73)
Microbiology
(58)
Virology
(56)
Human Viral Diseases
(55)
Viral Diseases
(55)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(48)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Etravirine concentrations in CSF in HIV-infected patients

Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV‐1‐associated neurocognitive impairment during antiretroviral treatment switch

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group

Elvitegravir concentrations in seminal plasma in HIV‐1‐infected men

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the ARTEN study)

Etravirine concentrations in seminal plasma in HIV-infected patients

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort

New patterns of HIV-1 resistance during HAART

Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients

Long-Term Prognosis of HIV-Infected Patients with Kaposi Sarcoma Treated with Pegylated Liposomal Doxorubicin

Trends in mortality and antibiotic resistance among HIV‐infected patients with invasive pneumococcal disease

Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144‐week final data from the STOPAR study

Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study

Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

HIV-1 infected patients older than 50 years. PISCIS cohort study

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

Suchergebnisse filtern